MetaCap

Cognition Therapeutics (CGTX) vs Coherus Oncology (CHRS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cognition Therapeutics (CGTX) has outperformed Coherus Oncology (CHRS) over the past year, losing 58.1% versus a loss of 68.1%. Over five years, CGTX leads with a -93.5% price change compared with -98.0% for CHRS. Coherus Oncology is the larger company by market cap ($57.1 million vs $55.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CGTX-58.12%CHRS-68.12%
+126%+24%-77%
Nov 21, 20251 yearNov 20, 2026
CGTX-94.35%CHRS-98.00%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CGTX versus CHRS key metrics
MetricCGTXCHRS
Share price$0.5822$0.3698
Market cap$55.37M$57.15M
1-day change-3.06%-4.47%
YTD return-56.87%-73.96%
1-year return-58.12%-68.12%
5-year return-93.47%-97.99%
EPS (TTM)$-0.16$-1.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$42.17M
Revenue growth (YoY)—+59.81%
Net income (latest FY)$-23.49M$168.02M
Gross margin—67.24%
Operating margin—-429.51%
Net margin—398.43%
52-week high$1.81$2.62
52-week low$0.55$0.3628
Distance from 52-week high-67.83%-85.86%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+471.97%+1995.73%
Average volume464.94K1.80M
Shares outstanding95.10M154.54M
Employees14144
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CGTX has outperformed CHRS by 10.0 percentage points over the past year.

About Cognition Therapeutics

CGTX stock →

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees

About Coherus Oncology

CHRS stock →

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees

CGTX vs CHRS FAQ

Which is bigger, Cognition Therapeutics or Coherus Oncology?

Coherus Oncology (CHRS) is larger, with a market capitalization of $57.15M compared with $55.37M for Cognition Therapeutics (CGTX).

Which stock has performed better over the past year, CGTX or CHRS?

CGTX returned -58.12% over the past 12 months, compared with -68.12% for CHRS (price return, excluding dividends). Past performance does not predict future results.

Are Cognition Therapeutics and Coherus Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons